Anika Therapeutics (NASDAQ: ANIK) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.
This table compares Anika Therapeutics and Alexion Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Anika Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.
Insider and Institutional Ownership
84.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 94.2% of Alexion Pharmaceuticals shares are held by institutional investors. 6.6% of Anika Therapeutics shares are held by insiders. Comparatively, 4.4% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Anika Therapeutics and Alexion Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Anika Therapeutics||$111.36 million||7.38||$56.02 million||$2.26||24.80|
|Alexion Pharmaceuticals||$3.41 billion||9.35||$1.34 billion||$2.31||61.83|
Alexion Pharmaceuticals has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent recommendations for Anika Therapeutics and Alexion Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Alexion Pharmaceuticals has a consensus price target of $158.26, indicating a potential upside of 10.80%. Given Alexion Pharmaceuticals’ higher probable upside, analysts plainly believe Alexion Pharmaceuticals is more favorable than Anika Therapeutics.
Alexion Pharmaceuticals beats Anika Therapeutics on 9 of the 14 factors compared between the two stocks.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.